A $4.9 billion hole has appeared in Gilead’s pipeline. After years of setbacks, the big biotech dealt a final blow to its ...

One of Chris Boerner’s first tours as the new CEO of Bristol Myers Squibb was of a 256,000 square-foot research facility in ...

Last year was a difficult one for ex-Stanford president Marc Tessier-Lavigne, Ph.D. An investigation into his prior research ...

Bristol Myers Squibb is the latest large pharma to wield the restructuring ax, with plans to cut $1.5 billion in costs by the ...

Medtronic has secured FDA approval for its first closed-loop spinal cord stimulator, designed to take in signals from the ...

In recent years, artificial intelligence programs for drug design have steadily shown they can help explore far beyond just ...

After hanging out the for sale sign and filing for bankruptcy ear | According to Invitae the transaction covers ...

After BioMarin’s new leadership conducted a “strategic R&D asset review,” three of its “most productive” assets are being ...

As a whole, Boston Scientific reported a 13.8% increase in quarterly revenue, for $3.86 billion in net sales. That outpaced ...

If you asked an AI to generate a brand-new drug discovery biotech with a team of some of the biggest names in the biz for you ...

Parexel has struck a multi-year deal with Palantir Technologies to integrate its artificial intelligence systems into Parexel ...

Regeneron is signing another major deal in gene editing—and, this time, it’s Mammoth. Mammoth Biosciences, that is. The ...